अन्य औषधि, खाना र जडीबुटी उत्पादनले Doxorubicin को काम बदल्न सक्छन्। यस पृष्ठका सबै कुरा Doxorubicin कै FDA-स्वीकृत लेबलबाट आएका हुन् — मुख्य गाइडकै स्रोतबाट।
लेबलले जसरी समूह बनाएको छ, त्यसरी नै राखिएको छ। प्रत्येक नाम त्यस औषधिको NepalDoc गाइडसँग जोडिन्छ; लेबलले औषधिको नाम नभई वर्ग मात्र भनेको ठाउँमा लेबलकै शब्द उद्धृत गरिएको छ।
Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4, CYP2D6, and P-gp Concomitant use of doxorubicin hydrochloride with inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp), increased concentrations of doxorubicin, which may increase the incidence and severity of adverse reactions of doxorubicin hydrochloride.Concomitant Use of Trastuzumab Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction. Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab . Patients receiving doxorubicin after stopping treatment with trastuzumab may also be at an increased risk of developing cardiotoxicity.Concomitant Use of Dexrazoxane Do not administer dexrazoxane as a cardioprotectant at the initiation of doxorubicin hydrochloride-containing chemotherapy regimens.Concomitant Use of 6-Mercaptopurine Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity.Doxorubicin को लेबलले ३ औषधिको नाम लिएको छ, जुन NepalDoc मा पनि छन्।
यहाँ नाम भएका यी औषधिका आफ्नै अन्तरक्रिया पृष्ठ पनि छन्:
• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp • Do not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction
7.1 Effect of Other Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4, CYP2D6, and P-gp Concomitant use of doxorubicin hydrochloride with inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp), increased concentrations of doxorubicin, which may increase the incidence and severity of adverse reactions of doxorubicin hydrochloride. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp. Inducers of CYP3A4, CYP2D6, or P-gp Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp. Paclitaxel Paclitaxel, when given prior to doxorubicin hydrochloride, increases the plasma-concentrations of doxorubicin and its metabolites. Administer Doxorubicin Hydrochloride Injection prior to paclitaxel if used concomitantly.
7.2 Concomitant Use of Trastuzumab Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction. Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab . Patients receiving doxorubicin after stopping treatment with trastuzumab may also be at an increased risk of developing cardiotoxicity. Trastuzumab may persist in the circulation for up to 7 months. Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracyclines are used before this time, carefully monitor cardiac function.
7.3 Concomitant Use of Dexrazoxane Do not administer dexrazoxane as a cardioprotectant at the initiation of doxorubicin hydrochloride-containing chemotherapy regimens. In a randomized trial in women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin hydrochloride-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%; p = 0.007) and shorter time to progression compared to doxorubicin hydrochloride-based chemotherapy alone.
7.4 Concomitant Use of 6-Mercaptopurine Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity. In 11 patients with refractory leukemia treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase.
Doxorubicin गाइड · सबै अन्तरक्रिया पृष्ठहरू · औषधि A–Z
यो पृष्ठले Doxorubicin को FDA-स्वीकृत लेबलको सारांश जानकारीका लागि दिन्छ — यो चिकित्सकीय सल्लाह होइन। तपाईंले लिने हरेक औषधि, सप्लिमेन्ट र जडीबुटी उत्पादनबारे आफ्नो डाक्टर वा फार्मासिस्टलाई सधैं भन्नुहोस्।
यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। NLEM सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।
नेपालडकका सबै खण्ड, एकै ठाउँमा।
विशेषज्ञताअनुसार नेपालभरका डाक्टर खोज्नुहोस्।